E-viri
Recenzirano
Odprti dostop
-
Gomides, Ana Paula Monteiro; de Albuquerque, Cleandro Pires; Santos, Ana Beatriz Vargas; Amorim, Rodrigo Balbino Chaves; Bértolo, Manoel Barros; Júnior, Paulo Louzada; Santos, Isabela Araújo; Giorgi, Rina Dalva Neubarth; Sacilotto, Nathalia de Carvalho; Radominski, Sebastião Cezar; Borghi, Fernanda Maria; Guimarães, Maria Fernanda B Resende; Pinto, Maria Raquel da Costa; Resende, Gustavo Gomes; Bonfiglioli, Karina Rossi; Silva, Henrique Carriço da; Sauma, Maria de Fátima Lobato da Cunha; Sauma, Marcel Lobato; de Medeiros, Júlia Brito; Pereira, Ivânio Alves; de Castro, Gláucio Ricardo Wernwer; Brenol, Claiton Viegas; Xavier, Ricardo Machado; da Mota, Licia Maria Henrique; Pinheiro, Geraldo da Rocha Castelar
PloS one, 03/2019, Letnik: 14, Številka: 3Journal Article
The treatment of rheumatoid arthritis (RA) has evolved rapidly in recent years. Nonetheless, conventional synthetic disease-modifying drugs (csDMARDs) remain the gold standard for RA treatment. The treatment for RA is expensive and this has a negative impact on public health. Given the low cost of csDMARDs compared to those of other treatment strategies, it is important to manage this type of treatment properly. Information on the duration of use of each drug and the reasons for their discontinuation is relevant to medical practitioners as it could improve the information available regarding side effects and their proper management. Moreover, data from clinical practice in the population can provide health care managers with information for resource allocation and optimization of csDMARD use with a consequent cost reduction in the treatment of RA. In this cross-sectional study, we aimed to describe the use of csDMARDs in public health services in Brazil, emphasizing on the duration of use and reasons for discontinuation of each drug. This study is a part of the REAL, a multicenter project that evaluated Brazilian patients with RA from eleven rheumatology services from August to October 2015. Patients were examined clinically, and an analysis of complementary exams and medical records was performed. A total of 1125 patients were included. 98.5% were women with a median age of 55.6 years. 36% and 90.84% patients were using biological disease-modifying drugs (bDMARDs) and csDMARDs, respectively. The duration of use and doses of each medication and the causes of suspension were analyzed. Most of the patients analyzed in this study were using csDMARDs for prolonged periods and methotrexate showed the longest duration of use. Interruption indexes due to ineffectiveness and side effects were analyzed. The knowledge of common adverse effects may alert attending physicians to the proper management of effective and low-cost therapeutic groups.
Avtor
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.